Literature DB >> 2504144

Metabolic properties of a homogeneous proteoglycan of a haemopoietic stem cell line, FDCP-mix.

A J Morris1, T M Dexter, J T Gallagher.   

Abstract

A biochemical analysis has been carried out of metabolically labelled proteoglycans and glycosaminoglycans synthesized by a haemopoietic multipotential stem cell line, FDCP-mix. The only proteoglycan identified in these multipotential cells was a homogeneous component that contained chondroitin 4-sulphate chains (Mr approximately 10,000) arranged in close proximity in a proteinase-resistant domain of the protein core. Small quantities of free chondroitin 4-sulphate were also detected. Following a 48 h incubation with Na2 35SO4 the majority of the 35S-radiolabelled proteoglycans (approximately 80%) were associated with the cells, mainly in an intracellular compartment, and the remaining 20% were in the culture medium. Pulse-chase studies demonstrated two turnover pathways for the newly synthesized cellular proteoglycans. In the minor pathway, the proteoglycans were secreted rapidly into the medium without any discernable structural modification. In the major pathway the proteoglycans seemed to be transferred into a storage compartment from which the intact macromolecules were not secreted. Eventually, these proteoglycans were degraded to yield free polysaccharide chains and these chains were then released into the medium, but only at a relatively slow rate. There was very little intracellular degradation of chondroitin sulphate chains. The pathway to polysaccharide secretion was a slow stepwise process with a time-lag of about 5 h between proteoglycan synthesis and the appearance of free chondroitin sulphate and a second time-lag, also of about 5 h, before these chains began to be secreted. The existence of separate secretory pathways for proteoglycans and chondroitin sulphate chains is an interesting characteristic that seems to distinguish proteoglycan metabolism in primitive multipotent stem cells from related metabolic processes in mature haemopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504144      PMCID: PMC1138693          DOI: 10.1042/bj2600479

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

1.  Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates.

Authors:  H Saito; T Yamagata; S Suzuki
Journal:  J Biol Chem       Date:  1968-04-10       Impact factor: 5.157

2.  Secretory and surface components released by proteolysis of lymphoid cells and their isolated membranes.

Authors:  M Jett; G A Jamieson
Journal:  Biochem Biophys Res Commun       Date:  1973-12-19       Impact factor: 3.575

3.  Differential sulphation of chondroitins in murine T and B lymphocytes and lymphoma cells.

Authors:  C C Rider; G W Hart
Journal:  Mol Immunol       Date:  1987-09       Impact factor: 4.407

4.  A proteoglycan form of heparin and its degradation to single-chain molecules.

Authors:  H C Robinson; A A Horner; M Höök; S Ogren; U Lindahl
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

5.  Changes in glycosaminoglycan biosynthesis during differentiation in vitro of human monocytes.

Authors:  S O Kolset; L Kjellén; R Seljelid; U Lindahl
Journal:  Biochem J       Date:  1983-03-15       Impact factor: 3.857

6.  Native heparin from rat peritoneal mast cells.

Authors:  R W Yurt; R W Leid; K F Austen
Journal:  J Biol Chem       Date:  1977-01-25       Impact factor: 5.157

7.  Effect of p-nitrophenyl-beta-D-xyloside on proteoglycan and glycosaminoglycan biosynthesis in rat serosal mast cell cultures.

Authors:  R L Stevens; K F Austen
Journal:  J Biol Chem       Date:  1982-01-10       Impact factor: 5.157

8.  The isolation, identification and characterization of sulfated glycosaminoglycans synthesized in vitro by human eosinophils.

Authors:  D D Metcalfe; J Litvin; S I Wasserman
Journal:  Biochim Biophys Acta       Date:  1982-04-13

9.  Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate.

Authors:  E Razin; R L Stevens; F Akiyama; K Schmid; K F Austen
Journal:  J Biol Chem       Date:  1982-06-25       Impact factor: 5.157

10.  Growth of factor-dependent hemopoietic precursor cell lines.

Authors:  T M Dexter; J Garland; D Scott; E Scolnick; D Metcalf
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  6 in total

1.  Proteoglycan synthesis in human and murine haematopoietic progenitor cell lines: isolation and characterization of a heparan sulphate proteoglycan as a major proteoglycan from the human haematopoietic cell line TF-1.

Authors:  G Stöcker; Z Drzeniek; U Just; W Ostertag; B Siebertz; H Greiling; H D Haubeck
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

2.  Proteoglycan synthesis in haematopoietic cells: isolation and characterization of heparan sulphate proteoglycans expressed by the bone-marrow stromal cell line MS-5.

Authors:  Z Drzeniek; B Siebertz; G Stöcker; U Just; W Ostertag; H Greiling; H D Haubeck
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

3.  Expression of glypican-4 in haematopoietic-progenitor and bone-marrow-stromal cells.

Authors:  B Siebertz; G Stöcker; Z Drzeniek; S Handt; U Just; H D Haubeck
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

4.  Expression of proteoglycan core proteins in human bone marrow stroma.

Authors:  K P Schofield; J T Gallagher; G David
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

5.  Proteoglycan synthesis in human erythroleukaemia (HEL) cells.

Authors:  B P Schick; S Senkowski-Richardson
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

6.  Differentiation of primitive human multipotent hematopoietic progenitors into single lineage clonogenic progenitors is accompanied by alterations in their interaction with fibronectin.

Authors:  C M Verfaillie; J B McCarthy; P B McGlave
Journal:  J Exp Med       Date:  1991-09-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.